A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

One Antibody Trial Is Halted, While Others Continue


An ongoing trial of the antibody bamlanivimab—administered with remdesivir, an antiviral medication—on hospitalized COVID-19 patients has been halted by bamlanivimab’s manufacturer Eli Lilly. The decision was made to stop the trial after evidence showed the therapy had little positive effect on those with serious COVID-19 illness. However, the pharmaceutical company is continuing trials on bamlanivimab in different settings, including evaluating its effect on patients in the earliest stages of COVID-19. Click here to read more.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy